New CEO at Roche's Pharma Division

New CEO at Roche's Pharma Division

31.08.2012 - Swiss drug giant Roche AG has filled the leadership gap at its pharma division after its former head Pascal Soriot left the company to become CEO of British-Swedish pharma major AstraZeneca.

From 1 September, Daniel O’Day, currently COO at Roche Diagnostics, will step in. O’Day will be succeeded by Roland Diggelmann, currently Head of the Asia-Pacific Region within Roche Diagnostics who has been appointed as a new member of the Executive Committee by the Board of Directors. Daniel O’Day began his career in 1987 at Roche in the U.S. Pharmaceuticals organisation in Sales and Marketing. Following that, he held various positions in Roche Pharma in Switzerland, Japan, and Denmark. In 2006, O’Day joined Roche Diagnostics and became Head of the business area „Molecular Diagnostics“. On January 1 2010 he was appointed Chief Operating Officer for Roche’s global diagnostics business.

29.05.2012 Alan Schafer is to head British biomarker specialist Population Genetics Technologies Ltd.

The firm's new CEO has a track record in research, Big Pharma management and building new businesses. The former Wellcome Trust’s Director of Science Funding is currently an Adjunct Professor of Innovation at the Imperial College London. He has also served as Global Vice-President of Technology Development at GlaxoSmithKline, and co-founded the functional genomics firm Hexagen.

30.05.2012 EuropaBio has named Miriam Gargesi as its new Director of Healthcare Biotechnology.

She arrives from the Brussels-based EDMA (European Diagnostics Manufacturers Association) where she was the Director for Public Affairs and Communications. Gargesi worked previously as a consultant for Hill & Knowlton and for Kreab
Gavin Anderson. She brings the EDMA extensive knowledge of policymaking gained serving in the Italian Parliament and at the House of Commons in London. Gargesi takes over from Ludovic Lacaine, who had led the division since 2009.

22.06.2012 In June, Ireland's Shire plc (Dublin) appointed a new Chief of Business Developer and Global Head of Human Resources. David Colpman, currently Senior Vice President, will take over that responsibility from Barbara Deptula, Shire's Executive Vice President and Chief Corporate Development Officer, who will retire at the end of June.

Colpman, who has been with Shire for 12 years, brings in extensive experience in dealmaking. Prior to Shire, he worked at Glaxo Wellcome, Novo Nordisk and Boots Pharmaceuticals in a variety of business development and commercial roles. He started his industry career at ICI (now AstraZeneca) in formulation and manufacturing. Ann Judge (not pictured), Senior Vice President of Shire’s global Human Resources (HR) team, has also joined the Shire Leadership

26.06.2012 Swiss Molecular Partners AG (Zurich­-Schlieren) has appointed hematologist Lisa Rojk­jaer as its new Chief Medical Officer. Rojk­jaer, who comes in from German antibody specialist MorphoSys AG, has a track record of 10 years in bio­pharmaceutical drug development.

She will be heading up all clinical activities at Molecular Partners. Prior to her post as Vice President and Head of Clinical Development at Morphosys, she held a variety of senior positions in clinical development and medical affairs at Novartis and Novo Nordisk.

25.06.2012 Swiss Cytos Biotechnology Ltd. (Schlieren) has nominated the former CEO of Micromet Inc., Christian Itin, as its Non-executive Director. The biologist resigned from his former post after selling the firm for US$1.16bn in cash to Amgen.

Itin spent 13 years with Micro­met. In 1999, Itin also co-founded Zyomyx Inc., a protein chip company based in the US.

09.07.2012 InDex Pharmaceuticals (Stockholm) has added Stig Løkke Pedersen to its board. The former VP Commercial Operations at H. Lundbeck A/S brings in 25 years of leadership experience and networking in the biotech and pharmaceutical industries.

Pedersen joined Lundbeck in 1992 as CBO, and was selected to join its corporate senior management in 1998. There he served as Executive Vice President from 2003-2011. Pedersen is a partner at Executive Capital A/S and also serves as the Chairman of the Board of Directors at Chemo-metec A/S and Nuevolution A/S.

05.07.2012 Swedish Microbiology specialist Medivir AB has appointed Henric Juserius to head the company's commercial activities. The former Commercial Director (Nordic region) of Actelion Pharmaceuticals will have overall responsibility for the firm's marketing and sales.

His main task will be to prepare the commercial launch of Medivir's Phase III product TMC435, which is being co-developed with Janssen Pharma-ceuticals for hepatitis C. 

02.07.2012 Dr. Christian Patermann, the mastermind behind the EU's bioeconomy strategy, has been honoured by the Accademia dei Georgofili in Florence. In a ceremony in the Uffizi at the end of April, Patermann was appointed as a member of the the first public association in Europe dedicated to agrarian studies.

As Programme Director Biotechnology, Agriculture and Food at DG Research of the European Commission, Patermann drafted the EU's knowledge-based bioeconomy plans.

25.07.2012 Oslo-based DiaGenic ASA will have a new CEO in September: Paul de Potocki will succeed Henrik Lund, who has led the development of DiaGenic on an interim basis since April 2012.

Before de Potocki moved to DiaGenic, he was CEO of Aerocrine AB, a Swedish medical device and diagnostic company. Prior to joining Aerocrine, he served as Senior Vice President, Commercial and Strategic Development at Biovitrum AB. He has also served as Executive Vice President, Strategic Marketing at the German company Fresenius Kabi, as well as Divisional Vice President, Global Sales and Strategic Marketing with Pharmacia. Before this, he held various international commercial management positions within the Unilever group. Henrik Lund will resume his former position as chairman of DiaGenic.

18.07.2012 Ark Therapeutics Group (London) has appointed Dr David Venables as its new CEO from the beginning of August.

Since joining the Board in April of this year, he has focused on the development of Ark's viral development and manufacturing capabilities based in Kuopio, Finland. Martyn Williams, who joined the Company in October 1998 as Finance Director and became CEO in mid 2010, will hand over to Venables and leave the Company at the End of July.

Vorherige Seite2/6Nächste Seite


LentiKat’s offers an unusual investment opportunity

LentiKat’s owns, manufactures and distributes a patented immobilization into lentil-shaped Lentikats Biocatalysts. The unique lentil-like shape of the Lentikats Biocatalyst ensures unlimited diffusion of substrate(s) into any part of the matrix, while still retaining a convenient size for easy separation from the reaction medium. They find application in the Pharma & Food industry (including bio-based chemicals), Wastewater treatment as well as Biofuels. more...

Product of the week


Job Advert

Sales Manager

celares GmbH is a Berlin based drug delivery company focused on chemical modifications of biological drugs. We offer customized development services for international pharma and biopharma companies and have manufacturing capabilities for key starting materials used for the preparation of pharmaceutical drugs. For the intensification of our own sales activities we are looking for a sales manager. more...


All Events



BioVaria 2015

Stock list

All quotes


  • CYTOS1.32 CHF30.69%
  • WILEX5.08 EUR17.32%
  • SYNGENTA339.90 CHF8.11%


  • THERAMETRICS0.07 CHF-12.50%
  • MEDIGENE10.26 EUR-6.39%
  • MOLOGEN4.85 EUR-1.82%


  • 4SC5.20 EUR306.2%
  • WILEX5.08 EUR77.6%
  • PAION2.86 EUR21.7%


  • BIOTEST71.20 EUR-26.7%
  • THERAMETRICS0.07 CHF-22.2%
  • MEDIGENE10.26 EUR-16.8%


  • SANTHERA98.00 CHF2362.3%
  • CYTOS1.32 CHF500.0%
  • WILEX5.08 EUR483.9%


  • MOLOGEN4.85 EUR-56.0%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.30 EUR-27.7%

No liability assumed, Date: 04.05.2015

Current issue

All issues